Onodera, M.; Kitahara, S.; Sato, Y.; Kawamata, T.; Muragaki, Y.; Masamune, K.
Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583. Pharmaceuticals 2025, 18, 1586.
https://doi.org/10.3390/ph18101586
AMA Style
Onodera M, Kitahara S, Sato Y, Kawamata T, Muragaki Y, Masamune K.
Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583. Pharmaceuticals. 2025; 18(10):1586.
https://doi.org/10.3390/ph18101586
Chicago/Turabian Style
Onodera, Mikoto, Shuji Kitahara, Yasuto Sato, Takakazu Kawamata, Yoshihiro Muragaki, and Ken Masamune.
2025. "Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583" Pharmaceuticals 18, no. 10: 1586.
https://doi.org/10.3390/ph18101586
APA Style
Onodera, M., Kitahara, S., Sato, Y., Kawamata, T., Muragaki, Y., & Masamune, K.
(2025). Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583. Pharmaceuticals, 18(10), 1586.
https://doi.org/10.3390/ph18101586
